For now, care must be taken before designating Tregs to be responsible for IL-33-mediated CRC (in particular APC-mutation-mediated CRC) in settings where there is a concomitant rise in tumour Treg infiltration and increased cancer burden, in the absence of functional assessments. Here, IL33 is linked to neoplasm.